Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Nabriva Therapeutics announced earnings per share of $-1.37 on revenue of $487K. Analysts polled by Investing.com anticipated EPS of $-0.3467 on revenue of $7.3M.
Nabriva Therapeutics shares are up 28% from the beginning of the year, still down 86.01% from its 52 week high of $8.29 set on August 6, 2020. They are outperforming the S&P 500 which is up 17.92% from the start of the year.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings beat by J&J on July 21, who reported EPS of $2.48 on revenue of $23.31B, compared to forecasts EPS of $2.29 on revenue of $22.49B.
UnitedHealth had beat expectations on July 15 with second quarter EPS of $4.7 on revenue of $71.32B, compared to forecast for EPS of $4.43 on revenue of $69.51B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar